Work

Breakthroughs of bispecific antibodies therapy in multiple myeloma: latest updates from 2025 ASH

Year: 2026

Type: article

Abstract: Bispecific antibodies (BsAbs), which simultaneously target two antigens and redirect immune T cells toward tumor cells, have emerged as one of the most promising immunotherapeutic strategies for multiple myeloma (MM). Based on previously reported clinical data, several BsAbs have been approved for MM patients who relapsed in late-line treatment. At the 2025 ASH Annual Meeting, pivotal trials presented updated findings on BsAbs targeting B-cell maturation antigen (BCMA), G-protein-coupled receptor family C group 5 member D (GPRC5D), and Fc receptor-homolog 5 (FcRH5), evaluated as monotherapies or in combination regimens across patient populations, both at initial diagnosis and at relapse. Here, we summarize the remarkable outcomes from the key clinical trials.

Source: Biomarker Research

DOI: 10.1186/s40364-026-00912-4

Authors: Bihuan Zhao, Qiling Bu, Ai-Li Chen, Hong-Hu Zhu

Institutions: Capital Medical University, Beijing Chao-Yang Hospital, Capital Medical University

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,890